|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C11orf58 |
Gene summary for C11ORF58 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C11orf58 | Gene ID | 10944 |
| Gene name | chromosome 11 open reading frame 58 | |
| Gene Alias | IMAGE145052 | |
| Cytomap | 11p15.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | O00193 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10944 | C11orf58 | CA_HPV_1 | Human | Cervix | CC | 3.28e-13 | 1.48e-01 | 0.0264 |
| 10944 | C11orf58 | CA_HPV_3 | Human | Cervix | CC | 5.81e-06 | 2.03e-01 | 0.0414 |
| 10944 | C11orf58 | CCI_1 | Human | Cervix | CC | 3.46e-09 | -6.56e-01 | 0.528 |
| 10944 | C11orf58 | CCII_1 | Human | Cervix | CC | 1.43e-19 | -6.88e-01 | 0.3249 |
| 10944 | C11orf58 | sample1 | Human | Cervix | CC | 4.57e-02 | -3.58e-01 | 0.0959 |
| 10944 | C11orf58 | L1 | Human | Cervix | CC | 3.82e-10 | -3.33e-01 | 0.0802 |
| 10944 | C11orf58 | T1 | Human | Cervix | CC | 1.37e-14 | -4.63e-01 | 0.0918 |
| 10944 | C11orf58 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.34e-03 | 3.27e-01 | -0.1954 |
| 10944 | C11orf58 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.45e-05 | 4.05e-01 | 0.294 |
| 10944 | C11orf58 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.68e-04 | 5.04e-01 | 0.281 |
| 10944 | C11orf58 | A015-C-203 | Human | Colorectum | FAP | 7.60e-13 | -8.50e-02 | -0.1294 |
| 10944 | C11orf58 | A002-C-201 | Human | Colorectum | FAP | 1.34e-03 | -1.44e-01 | 0.0324 |
| 10944 | C11orf58 | A001-C-108 | Human | Colorectum | FAP | 4.95e-06 | -6.50e-02 | -0.0272 |
| 10944 | C11orf58 | A002-C-205 | Human | Colorectum | FAP | 1.42e-06 | -1.26e-01 | -0.1236 |
| 10944 | C11orf58 | A015-C-006 | Human | Colorectum | FAP | 4.35e-04 | -7.80e-02 | -0.0994 |
| 10944 | C11orf58 | A015-C-106 | Human | Colorectum | FAP | 1.10e-02 | 5.95e-03 | -0.0511 |
| 10944 | C11orf58 | A002-C-114 | Human | Colorectum | FAP | 3.76e-04 | -1.12e-01 | -0.1561 |
| 10944 | C11orf58 | A015-C-104 | Human | Colorectum | FAP | 6.42e-12 | 2.48e-02 | -0.1899 |
| 10944 | C11orf58 | A001-C-014 | Human | Colorectum | FAP | 4.35e-03 | -6.48e-02 | 0.0135 |
| 10944 | C11orf58 | A002-C-016 | Human | Colorectum | FAP | 9.55e-06 | -8.85e-02 | 0.0521 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C11orf58 | SNV | Missense_Mutation | c.133N>G | p.Met45Val | p.M45V | O00193 | protein_coding | deleterious(0) | benign(0.003) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| C11orf58 | SNV | Missense_Mutation | rs757516929 | c.415N>A | p.Asp139Asn | p.D139N | O00193 | protein_coding | tolerated(0.3) | possibly_damaging(0.473) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C11orf58 | insertion | In_Frame_Ins | novel | c.496_497insTCAATC | p.Lys166delinsIleAsnGln | p.K166delinsINQ | O00193 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| C11orf58 | SNV | Missense_Mutation | c.123N>A | p.Phe41Leu | p.F41L | O00193 | protein_coding | deleterious(0) | benign(0.023) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C11orf58 | SNV | Missense_Mutation | novel | c.293N>A | p.Arg98Gln | p.R98Q | O00193 | protein_coding | tolerated(0.07) | probably_damaging(0.947) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| C11orf58 | SNV | Missense_Mutation | rs752265677 | c.374N>G | p.Asp125Gly | p.D125G | O00193 | protein_coding | tolerated(0.38) | benign(0.003) | TCGA-EY-A547-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C11orf58 | insertion | Frame_Shift_Ins | novel | c.495_496insA | p.Asp168ArgfsTer7 | p.D168Rfs*7 | O00193 | protein_coding | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| C11orf58 | insertion | Nonsense_Mutation | novel | c.524_525insCTGAGAAA | p.Met175IlefsTer2 | p.M175Ifs*2 | O00193 | protein_coding | TCGA-D1-A102-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| C11orf58 | insertion | Frame_Shift_Ins | novel | c.501dupA | p.Asp168ArgfsTer7 | p.D168Rfs*7 | O00193 | protein_coding | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| C11orf58 | SNV | Missense_Mutation | c.16G>C | p.Glu6Gln | p.E6Q | O00193 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-34-2600-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |